Additionally, in the genetic models, no differences were observed in carriers of wild homozygote, heterozygote, or mutated homozygous for achieving NEDA-3, indicating no association between genetic variant HLA-DRB1*0403 and the therapeutic response to disease-modifying therapies in MS patients. The gene discussed is HLA-DRB1; the disease is myeloid sarcoma.